A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Virology Bookmark and Share

Virology

City of Hope’s Department of Virology strives to better understand the origin and development of herpes simplex virus and other herpes viruses, the biology of cytomegalovirus (a prime concern for HIV-infected and other immunocompromised patients such as transplant recipients), vaccine development and experimental therapies using gene transfer vectors such as adeno-associated virus (AAV) and lentivirus. Viral vectors have shown great promise in treating both cancers and HIV.

John A. Zaia, M.D., chair of the department, plays an integral role in the Hematopoietic Cell Transplantation Program’s efforts to understand the biology of cytomegalovirus (CMV)-related pneumonitis, which was a major limitation to the success of bone marrow transplantation, and later went on to develop the gene therapy program at City of Hope, focused on treatment of HIV with genetically modified stem cells and T cells.

The Department of Virology comprises more than 50 personnel, including professors, associate professors, support scientists, postdoctoral fellows, research associates, laboratory aides and administrative support.
 
Laboratory Research

John Zaia, M.D. – Antiviral Research
Zaia, department chair, joined City of Hope from Harvard in 1980. He directs two clinical research labs, the Cytomegalovirus (CMV) Lab and the HIV Lab, with interests in antiviral development in the area of herpes viruses and HIV. The CMV laboratory studies the immunobiology of CMV infection after hematopoietic cell transplantation (HCT) with emphasis on immune factors necessary for protection. The HIV laboratory focuses on developing new treatments for HIV/AIDS using optimal genetic vectors for anti-HIV gene transfer and novel drug therapy.

Edouard Cantin, Ph.D. – Neurovirology and Neuroimmunology
Cantin is director of the Laboratory of Neurovirology and Neuroimmunology. He investigates the role of the host immune response in the pathogenesis herpes simplex virus (HSV) infections in vivo, with particular emphasis on CNS infections and the regulation of latency. His laboratory is also investigating the mechanisms by which intravenous immunoglobulins (IVIG) act as a potent immunomodulatory drug to suppress virus induced hyper-inflammatory responses that in the CNS culminate in fatal encephalitis following infection with HSV or West Nile virus, or fatal pneumonia following infection with highly pathogenic influenza virus strains, such as pandemic H1N1. A long-term interest is to understand the genetic basis of innate resistance to HSV, as this may suggest rational approaches to controlling recurrent infections, and the development of serious diseases such as encephalitis.
 
Saswati Chatterjee, Ph.D. – Gene Therapy
Chatterjee directs the Adeno-Associated Virus (AAV) Laboratory and is interested in the biology of AAV vectors for therapeutic gene transfer. Her specific areas of interest include stem cell-based genetic therapies of acquired and inherited diseases, including HIV infection, cancer, cardiovascular and genetic diseases; virus discovery research in human stem cells and the study of genetic elements necessary for optimal gene-based therapies. She evaluates gene therapy approaches in both in vitro and in vivo pre-clinical models, with targeted progression toward clinical human gene therapy trials.

Don J. Diamond, Ph.D. – Vaccine Research
Don Diamond, Ph.D., associate chair and the Tim Nesvig Lymphoma Research Fellow at City of Hope, directs the Division of Translational Vaccine Research (TVR), which develops vaccines to combat hematologic malignancies, solid tumors, and infectious pathogens such as the herpesvirus, cytomegalovirus (CMV) and human immunodeficiency virus, or HIV. The prospect of an effective CMV vaccine means significant benefits for immunocompromised patients such as those with AIDS, or stem cell and solid organ transplant recipients. A therapeutic CMV peptide vaccine developed in the TVR is undergoing phase II human efficacy testing in City of Hope stem cell transplant recipients, while a second generation CMV vaccine based on the attenuated poxvirus MVA, or modified vaccinia Ankara, will initiate phase I human safety testing in fall 2013. A vaccine developed in the TVR also based on the MVA platform expressing unmutated p53 is undergoing phase I human testing in City of Hope gastrointestinal cancer patients. In the laboratory, we are refining a therapeutic platform based on attenuated Salmonella bacterium to treat a range of malignancies including pancreatic, skin and brain cancers. In collaboration with Peter Barry, Ph.D., of University of California at Davis and the National Primate Research Center, we are developing a prophylactic CMV vaccine that promises to control gestational infection that causes a wide range of birth defects that annually afflict close to 4,000 American children.

Jiing-Kuan Yee, Ph.D.Modeling human diseases with stem cells
Dr. Yee is interested in using cell reprogramming and gene editing to establish ex vivo human genetic disease models to explore the underlying disease mechanisms and develop therapeutic strategies for treatment.  He has established fibroblast-derived induced pluripotent stem cells (iPSCs) from spinal muscular atrophy and Wiskott-Aldrich syndrome patients.  He is studying the phenotypes of cells differentiated from these iPSC lines to understand the pathogenesis of the disease.  He is also using gene editing technology to modify the genome of the iPSCs to explore the possibility of treating these diseases with cell replacement therapy.
 
Translational Vaccine Research
The LVR was formed to address priorities in vaccine research that will potentially impact patient outcomes at City of Hope and other cancer centers worldwide.

Virology Faculty

Virology

Virology

City of Hope’s Department of Virology strives to better understand the origin and development of herpes simplex virus and other herpes viruses, the biology of cytomegalovirus (a prime concern for HIV-infected and other immunocompromised patients such as transplant recipients), vaccine development and experimental therapies using gene transfer vectors such as adeno-associated virus (AAV) and lentivirus. Viral vectors have shown great promise in treating both cancers and HIV.

John A. Zaia, M.D., chair of the department, plays an integral role in the Hematopoietic Cell Transplantation Program’s efforts to understand the biology of cytomegalovirus (CMV)-related pneumonitis, which was a major limitation to the success of bone marrow transplantation, and later went on to develop the gene therapy program at City of Hope, focused on treatment of HIV with genetically modified stem cells and T cells.

The Department of Virology comprises more than 50 personnel, including professors, associate professors, support scientists, postdoctoral fellows, research associates, laboratory aides and administrative support.
 
Laboratory Research

John Zaia, M.D. – Antiviral Research
Zaia, department chair, joined City of Hope from Harvard in 1980. He directs two clinical research labs, the Cytomegalovirus (CMV) Lab and the HIV Lab, with interests in antiviral development in the area of herpes viruses and HIV. The CMV laboratory studies the immunobiology of CMV infection after hematopoietic cell transplantation (HCT) with emphasis on immune factors necessary for protection. The HIV laboratory focuses on developing new treatments for HIV/AIDS using optimal genetic vectors for anti-HIV gene transfer and novel drug therapy.

Edouard Cantin, Ph.D. – Neurovirology and Neuroimmunology
Cantin is director of the Laboratory of Neurovirology and Neuroimmunology. He investigates the role of the host immune response in the pathogenesis herpes simplex virus (HSV) infections in vivo, with particular emphasis on CNS infections and the regulation of latency. His laboratory is also investigating the mechanisms by which intravenous immunoglobulins (IVIG) act as a potent immunomodulatory drug to suppress virus induced hyper-inflammatory responses that in the CNS culminate in fatal encephalitis following infection with HSV or West Nile virus, or fatal pneumonia following infection with highly pathogenic influenza virus strains, such as pandemic H1N1. A long-term interest is to understand the genetic basis of innate resistance to HSV, as this may suggest rational approaches to controlling recurrent infections, and the development of serious diseases such as encephalitis.
 
Saswati Chatterjee, Ph.D. – Gene Therapy
Chatterjee directs the Adeno-Associated Virus (AAV) Laboratory and is interested in the biology of AAV vectors for therapeutic gene transfer. Her specific areas of interest include stem cell-based genetic therapies of acquired and inherited diseases, including HIV infection, cancer, cardiovascular and genetic diseases; virus discovery research in human stem cells and the study of genetic elements necessary for optimal gene-based therapies. She evaluates gene therapy approaches in both in vitro and in vivo pre-clinical models, with targeted progression toward clinical human gene therapy trials.

Don J. Diamond, Ph.D. – Vaccine Research
Don Diamond, Ph.D., associate chair and the Tim Nesvig Lymphoma Research Fellow at City of Hope, directs the Division of Translational Vaccine Research (TVR), which develops vaccines to combat hematologic malignancies, solid tumors, and infectious pathogens such as the herpesvirus, cytomegalovirus (CMV) and human immunodeficiency virus, or HIV. The prospect of an effective CMV vaccine means significant benefits for immunocompromised patients such as those with AIDS, or stem cell and solid organ transplant recipients. A therapeutic CMV peptide vaccine developed in the TVR is undergoing phase II human efficacy testing in City of Hope stem cell transplant recipients, while a second generation CMV vaccine based on the attenuated poxvirus MVA, or modified vaccinia Ankara, will initiate phase I human safety testing in fall 2013. A vaccine developed in the TVR also based on the MVA platform expressing unmutated p53 is undergoing phase I human testing in City of Hope gastrointestinal cancer patients. In the laboratory, we are refining a therapeutic platform based on attenuated Salmonella bacterium to treat a range of malignancies including pancreatic, skin and brain cancers. In collaboration with Peter Barry, Ph.D., of University of California at Davis and the National Primate Research Center, we are developing a prophylactic CMV vaccine that promises to control gestational infection that causes a wide range of birth defects that annually afflict close to 4,000 American children.

Jiing-Kuan Yee, Ph.D.Modeling human diseases with stem cells
Dr. Yee is interested in using cell reprogramming and gene editing to establish ex vivo human genetic disease models to explore the underlying disease mechanisms and develop therapeutic strategies for treatment.  He has established fibroblast-derived induced pluripotent stem cells (iPSCs) from spinal muscular atrophy and Wiskott-Aldrich syndrome patients.  He is studying the phenotypes of cells differentiated from these iPSC lines to understand the pathogenesis of the disease.  He is also using gene editing technology to modify the genome of the iPSCs to explore the possibility of treating these diseases with cell replacement therapy.
 
Translational Vaccine Research
The LVR was formed to address priorities in vaccine research that will potentially impact patient outcomes at City of Hope and other cancer centers worldwide.

Virology Faculty

Virology Faculty

Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
NEWS & UPDATES
  • September is Prostate Cancer Awareness Month. Here, Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Services at City of Hope, explains the importance of understanding the risk factors for the disease and ways to reduce those risks, as well as overall prostate health. “Wha...
  • ** Learn more about prostate cancer risk, plus prostate cancer research and treatment, at City of Hope. ** Learn more about getting a second opinion at City of Hope by visiting us online or by calling 800-826-HOPE (4673). City of Hope staff will explain what’s required for a consult at City of Hope and he...
  • Childhood cancer survival rates have increased dramatically over the past 40 years. More than 80 percent of children with cancer now survive five years or more, which is a tremendous feat. Despite the survival rate increase, cancer continues to be the No. 1 disease killer and second-leading cause of death in ch...
  • Although a stem cell transplant can be a lifesaving procedure for people diagnosed with a blood cancer or blood disorder, the standard transplant may not be appropriate for all patients. This is because the conditioning regimen (the intensive chemotherapy and/or radiation treatments preceding the transplant) is...
  • Brain tumor removal would seem to be the obvious course of action in the wake of a brain tumor diagnosis, but that’s not always the case. Some tumors are too difficult for many surgeons to reach or too close to areas that control vital functions. Removing them just proves too risky. A new device being con...
  • Hijacking the same sorts of viruses that cause HIV and using them to reprogram immune cells to fight cancer sounds like stuff of the future. Some scientists believe that the future is closer than we think – and are now studying the approach in clinical trials at City of Hope. Immunotherapy is a promising approa...
  • Nausea is the one of the most well-known, and dreaded, side effects of cancer treatment — and with good reason. Beyond the quality-of-life issues that it causes, severe nausea can prevent patients from receiving enough nutrients and calories at a time when they need every edge they can get. A few simple actions...
  • With Labor Day just around the corner, summer is on its way out. But just because summertime is ending doesn’t mean we can skip sunscreen. Protection from ultraviolet (UV) radiation is needed all year round. Exposure to UV radiation — whether from the sun or from artificial sources such as sunlamps used i...
  • Undergoing reconstructive surgery may seem like a forgone conclusion for survivors of breast cancer, but that doesn’t appear to be the case. A new study has found that most breast cancer survivors who undergo a mastectomy decide against surgical reconstruction of their breasts. The reasons for such a deci...
  • Nearly four decades ago, City of Hope began its bone marrow transplant program. Its first transplant reunion celebration was a single patient and his donor, also his brother. This year, City of Hope welcomed hundreds of hematopoietic cell transplant (HCT) recipients to the annual bone marrow transplant/HCT reun...
  • The burgeoning type 2 diabetes epidemic casts a pall over the health of America’s public. New research now shows the looming threat is getting worse. Much worse. A diabetes trends study published earlier this month in the Lancet Diabetes and Endocrinology by researchers at the federal Centers for Disease Contro...
  • An aspirin a day might help keep breast cancer away for some breast cancer survivors, a new study suggests. Obese women who have had breast cancer could cut their risk of a recurrence in half if they regularly take aspirin or other nonsteroidal anti-inflammatory drugs, called NSAIDs, report researchers from the...
  • Christine Crews isn’t only a fitness enthusiast, she’s also a personal trainer and fitness instructor. Being active defines her life. So when she was diagnosed with bladder cancer at age 30, she decided she absolutely couldn’t let the disease interfere with that lifestyle. And it didn’t. For t...
  • Cancer treatment and the cancer itself can cause changes in your sense of taste or smell. These side effects typically subside after treatment ends, but there are ways to help alleviate those bitter and metallic tastes in your mouth. Here are tips from the National Cancer Institute to help keeps tastes and food...
  • Immunotherapy — using one’s immune system to treat a disease — has been long lauded as the “magic bullet” of cancer treatments, one that can be more effective than the conventional therapies of surgery, radiation or chemotherapy. One specific type of immunotherapy, called adoptive T cell thera...